Hims & Hers Health HIMS
- Market cap
- $6.5B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.5×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $2.6B
- +28% on a year ago
- Net margin
- −5.5%
- Free cash flow yield
- n/m
- not a meaningful number
Hims & Hers Health trades at 2.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $2.6B over the last twelve months, up 28% on a year earlier with a −6% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $226.7M+57% | $246.6M+48% | $278.2M+46% | $315.6M+52% | $401.6M+77% | $481.1M+95% | $586M+111% | $544.8M+73% | $599M+49% | $617.8M+28% | $608.1M+4% | $753.2M+38% | |
| Cost of revenue | $39.4M+30% | $42.6M+22% | $49.1M+31% | $59M+56% | $83.7M+112% | $111.6M+162% | $155.3M+217% | $128.6M+118% | $156.9M+88% | $173.4M+55% | $211.3M+36% | $272.4M+112% |
| Gross profit | $187.3M+64% | $204.1M+54% | $229.1M+49% | $256.6M+51% | $317.9M+70% | $369.5M+81% | $430.7M+88% | $416.2M+62% | $442.1M+39% | $444.4M+20% | $396.8M−8% | $480.8M+16% |
| SG&A | $152M+45% | $158.2M+40% | $165.1M+29% | $185.5M+34% | $226.9M+49% | $269.1M+70% | $279.8M+70% | $285.1M+54% | $312.8M+38% | $314.2M+17% | $331.7M+19% | $427.6M+50% |
| −$8.6M−57% | −$400K−97% | $9.9M | $11M | $22.4M | $18.6M | $57.9M+485% | $26.7M+142% | $11.8M−47% | $9.2M−51% | −$78.3M | −$97.2M | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$6.9M−63% | $2.2M | $12.4M | $13.4M | $23.6M | $22.3M+915% | $60.5M+388% | $32.9M+145% | $12.2M−48% | $18.4M−18% | −$101.6M | −$92.6M |
| $651K | $951K | $1.3M+230% | $127K | −$52M | −$3.7M | $11M+764% | −$9.7M | −$3.6M−93% | −$2.2M−40% | −$9.4M | −$6.3M−34% | |
| Net income | −$7.6M−60% | $1.2M | $11.1M | $13.3M | $75.6M | $26M+1990% | $49.5M+345% | $42.5M+220% | $15.8M−79% | $20.6M−21% | −$92.1M | −$86.3M |
| −$0.04−56% | $0.01 | $0.05 | $0.06 | $0.32 | $0.11+1000% | $0.20+300% | $0.17+183% | $0.06−81% | $0.08−27% | −$0.40 | −$0.37 | |
| 210.1M+2% | 211.6M+3% | 229.4M+11% | 234.8M+13% | 235.1M+12% | 247.7M+17% | 246.6M+8% | 256.8M+9% | 248.7M+6% | 266.2M+8% | 228.4M−7% | 231.7M−10% |
EPS, diluted: 7 periods, Q4 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY19: share-days: the 9-month average less the 6-month, weighted by days. 3 periods, Q4 FY20 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 3 periods, Q4 FY23 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Care Facilities nearest Hims & Hers Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| HIMSHims & Hers Health | $6.5B | n/m | 65.3× | 2.5× | +28% | −5.5% | |
| CHEChemed | $6.7B | 25.8× | 29.0× | 2.6× | +3% | 10.6% | |
| PACSPACS | $7.5B | 27.2× | 27.2× | 1.4× | +15% | 4.8% | |
| SHCSotera Health | $5.2B | 31.8× | 55.4× | 4.2× | +8% | 13.4% | |
| CONConcentra Group Holdings Parent | $5B | 25.5× | 17.5× | 2.2× | +14% | 8.7% | |
| LFSTLifeStance Health | $4.9B | 99.5× | 142× | 3.1× | +20% | 3.2% | |
| OPCHOption Care Health | $4.7B | 23.5× | 26.4× | 0.8× | +6% | 3.7% | |
| ENSGEnsign | $10.2B | 27.5× | 25.5× | 1.9× | +19% | 6.9% | |
| UHSUniversal Health Services | $11B | 7.6× | 13.6× | 0.6× | +10% | 8.4% | |
| NHCNational Healthcare | $3.7B | 26.5× | 21.4× | 2.4× | +7% | 9.0% | |
| DVADavita | $11.7B | 15.0× | 16.1× | 0.8× | +6% | 6.0% | |
| Peer median | $5.9B | 26.1× | 26.0× | 2.0× | +9% | 7.7% |
Investors who own it
Investors we follow who held Hims & Hers Health at the end of Jun 30, 2026, from their 13F filings.
- Baillie GiffordBaillie Gifford0.0% of portfolionew
More on Hims & Hers Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Care Facilities
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .